Ken Griffin Xtl Biopharmaceuticals LTD Put Options Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding XTLB
# of Institutions
6Shares Held
453KCall Options Held
0Put Options Held
0-
Noked Capital LTD Tel Aviv, L3199KShares$361,9760.02% of portfolio
-
Noked Israel LTD Ramat Hasharon, L3199KShares$361,9760.13% of portfolio
-
Morgan Stanley New York, NY33.2KShares$60,3340.0% of portfolio
-
Rhumbline Advisers Boston, MA6.52KShares$11,8640.0% of portfolio
-
Concourse Financial Group Securities, Inc. Birmingham, AL0Shares$00.0% of portfolio
About XTL BIOPHARMACEUTICALS LTD
- Ticker XTLB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 5,449,060
- Market Cap $9.92M
- Description
- XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Ye...